This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (DAZALS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05407324
Recruitment Status : Recruiting
First Posted : June 7, 2022
Last Update Posted : September 26, 2023
Sponsor:
Information provided by (Responsible Party):
Corcept Therapeutics

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to assess the safety and efficacy of CORT113176 (dazucorilant) in patients with Amyotrophic Lateral Sclerosis (ALS).

Condition or disease Intervention/treatment Phase
Amyotrophic Lateral Sclerosis Drug: Dazucorilant 300 mg Drug: Dazucorilant 150 mg Other: Placebo Phase 2

Detailed Description:

Eligible ALS patients will be randomized to one of three treatment arms (1:1:1) across the United States and Europe for a 24-week double-blind treatment period.

Patients who complete participation (i.e., complete all visits) in the double-blind treatment period will be eligible for participation in a 24-week open-label extension (OLE) study. A daily dose of 300 mg dazucorilant will be used in the 24-week OLE period.

Patients that complete the double-blind treatment period and who do not enter the OLE will enter the 24-week follow-up period.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 198 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of CORT113176 (Dazucorilant) in Patients With Amyotrophic Lateral Sclerosis (DAZALS)
Actual Study Start Date : November 15, 2022
Estimated Primary Completion Date : May 2024
Estimated Study Completion Date : November 2024

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: CORT113176 (Dazucorilant) 300 mg
300 mg of dazucorilant will be administered once daily.
 Drug: Dazucorilant 300 mg
300 mg of dazucorilant will be administered once daily in 4 softgel capsules of 75 mg dazucorilant/capsule.
Experimental: CORT113176 (Dazucorilant) 150 mg
150 mg of dazucorilant will be administered once daily.
 Drug: Dazucorilant 150 mg
Dazucorilant and placebo will be administered once daily in 4 softgel capsules, 2 capsules with 75 mg dazucorilant/capsule and 2 capsules of placebo equivalent.
Placebo Comparator: Placebo (matched to study drug)
Placebo will be administered once daily.
 Other: Placebo
Placebo will be administered once daily in 4 softgel capsules of placebo equivalent.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Change from Baseline to Week 24 in the ALS Functional Rating Scale-Revised (ALSFRS-R) total score. [ Time Frame: Baseline to Week 24 ]
  2. Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), treatment-related AEs, AEs by severity, and deaths due to AEs. [ Time Frame: Baseline to Week 24 ]

Secondary Outcome Measures :
  1. Change from Baseline to Week 24 in muscle strength (assessed using hand-held dynamometer). [ Time Frame: Baseline to Week 24 ]
  2. Change from Baseline to Week 24 in Percent Slow Vital Capacity [ Time Frame: Baseline to Week 24 ]
  3. Change from Baseline to Week 24 in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) [ Time Frame: Baseline to Week 24 ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female patients ≥18 years of age with Sporadic or familial ALS
  • If taking riluzole and/or edaravone, must be on a stable dose prior to Screening.

Exclusion Criteria:

  • History of a clinically significant non-ALS neurologic disorder
  • Inability to swallow capsules.
  • Human immunodeficiency virus (HIV) or current chronic/active infection with hepatitis C virus or hepatitis B virus
  • Women who are pregnant, planning to become pregnant, or are breastfeeding.
  • Use of non-invasive ventilation (NIV) or mechanical ventilation via tracheostomy, or on any form of oxygen supplementation.
  • Current or anticipated need of a diaphragm pacing system (DPS).
  • Currently using glucocorticoids or have a history of regular systemic glucocorticoid use within the last 12 months.
  • Previous exposure or treatment with glucocorticoid receptor modulators or antagonists.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05407324


Contacts
Layout table for location contacts
Contact: Clinical Trial Lead (650) 327-3270 study652@corcept.com

Locations
Show Show 26 study locations
Sponsors and Collaborators
Corcept Therapeutics
Investigators
Layout table for investigator information
Study Director: Grace Mann, PhD Corcept Therapeutics
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Corcept Therapeutics
ClinicalTrials.gov Identifier: NCT05407324    
Other Study ID Numbers: CORT113176-652
2021-005611-31 ( EudraCT Number )
First Posted: June 7, 2022    Key Record Dates
Last Update Posted: September 26, 2023
Last Verified: September 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Corcept Therapeutics:
ALS, Amyotrophic Lateral Sclerosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Sclerosis
Pathologic Processes
Neurodegenerative Diseases
Nervous System Diseases
 Neuromuscular Diseases
Spinal Cord Diseases
Central Nervous System Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases